NCT04849026View on ClinicalTrials.gov

Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

August 14, 2022

Study Completion Date

August 14, 2022

Conditions
Schizophrenia
Interventions
DRUG

Clozaril 100 mg (Clozapine)

2 Doses/Day for 10 days

DRUG

WID-CLZ18

2 Doses/Day for 10 days

Trial Locations (1)

Unknown

Whan In Pharm., Seoul

All Listed Sponsors
lead

Whanin Pharmaceutical Company

INDUSTRY

NCT04849026 - Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18 | Biotech Hunter | Biotech Hunter